Pancreatic Cancer Research

ResearcherUniversity of PittsburghNo recent work listed

Matthew A. Firpo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7983-3982; OpenAlex author ID A5003013528. Sources: OpenAlex.

Their work

Papers
22 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
77
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 3 papers · 2014: 4 papers · 2015: 2 papers · 2016: 1 paper · 2017: 2 papers · 2018: 3 papers · 2019: 4 papers · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper

Papers 22

  1. Multianalyte Serum Biomarker Panel for Early Detection of Pancreatic Adenocarcinoma. Co-author DOI 10.1200/cci.22.00160↗
  2. County-level Variation in Use of Surgery and Cancer-specific Survival for Stage I-II Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000003236↗
  3. Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative … Co-author DOI 10.1007/s11605-018-3953-0↗
  4. Disparities in utilization of treatment for clinical stage I-II pancreatic adenocarcinoma by area socioeconomic status and race/ethnicity. Co-author DOI 10.1016/j.surg.2018.10.035↗
  5. Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. Co-author DOI 10.1038/s41467-018-08109-6↗
  6. Hospital-level Variation in Utilization of Surgery for Clinical Stage I-II Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002404↗
  7. Causes of Death and Conditional Survival Estimates of Medium- and Long-term Survivors of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2018.2442↗
  8. Association of time-to-surgery with outcomes in clinical stage I-II pancreatic adenocarcinoma treated with upfront surgery. Co-author DOI 10.1016/j.surg.2017.10.054↗
  9. Pancreatic cancer as a sentinel for hereditary cancer predisposition. Co-author DOI 10.1186/s12885-018-4573-5↗
  10. Implications of inaccurate clinical nodal staging in pancreatic adenocarcinoma. First author DOI 10.1016/j.surg.2016.12.029↗
  11. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. Co-author DOI 10.1093/jnci/djw266↗
  12. Biomarkers in pancreatic adenocarcinoma: current perspectives. First author DOI 10.2147/ott.s100510↗
  13. BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages. Co-author DOI 10.1038/ncomms9695↗
  14. Early detection of sporadic pancreatic cancer: summative review. Co-author DOI 10.1097/mpa.0000000000000368↗
  15. HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. Co-author DOI 10.1002/nbm.3198↗
  16. Screening for pancreatic cancer. First author DOI 10.1016/j.yasu.2014.05.004↗
  17. The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/ncb2916↗
  18. Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer. First author DOI 10.1111/hpb.12199↗
  19. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. First author DOI 10.1097/mpa.0b013e31825e354d↗
  20. Screening for pancreatic cancer: why, how, and who? First author DOI 10.1097/sla.0b013e31825ffbfb↗
  21. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Co-author DOI 10.2174/1566524011313030003↗
  22. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Co-author DOI 10.1016/j.ccr.2011.03.002↗

Closest collaborators

The 25 strongest of 77 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sean J. Mulvihill · 21 shared papers, 2011–2023 · strength 1.54
  2. Courtney L. Scaife · 12 shared papers, 2013–2023 · strength 1.09
  3. Douglas S. Swords · 8 shared papers, 2016–2020 · strength 0.82
  4. Douglas G. Adler · 5 shared papers, 2013–2023 · strength 0.35
  5. Katherine E. Poruk · 5 shared papers, 2013–2023 · strength 0.34
  6. Ignacio Garrido‐Laguna · 2 shared papers, 2019–2023 · strength 0.23
  7. Alessandra Rosati · 2 shared papers, 2015–2023 · strength 0.17
  8. Vincenzo De Laurenzi · 2 shared papers, 2015–2023 · strength 0.17
  9. Maria Caterina Turco · 2 shared papers, 2015–2023 · strength 0.17
  10. Margot De Marco · 2 shared papers, 2015–2023 · strength 0.17
  11. Liberato Marzullo · 2 shared papers, 2015–2023 · strength 0.17
  12. Anirban Maitra · 3 shared papers, 2015–2019 · strength 0.15
  13. Josh M. Bleicher · 1 shared paper, 2023 · strength 0.14
  14. Kajsa E. Affolter · 1 shared paper, 2023 · strength 0.14
  15. Matthew H. G. Katz · 2 shared papers, 2017–2019 · strength 0.12
  16. Michela Capello · 2 shared papers, 2017–2019 · strength 0.12
  17. Leonidas E. Bantis · 2 shared papers, 2017–2019 · strength 0.12
  18. Randall E. Brand · 2 shared papers, 2017–2019 · strength 0.12
  19. Samir Hanash · 2 shared papers, 2017–2019 · strength 0.12
  20. Margaret A. Tempero · 2 shared papers, 2014–2017 · strength 0.09
  21. Shane A. J. Lloyd · 1 shared paper, 2019 · strength 0.09
  22. Joshua David Gruhl · 1 shared paper, 2019 · strength 0.09
  23. Haley L. Peters · 1 shared paper, 2019 · strength 0.07
  24. Jody V. Vykoukal · 1 shared paper, 2019 · strength 0.07
  25. Vincent Bernard · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.